Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) reported Q1 2026 financial results...
Finanical Reports
Mindray Reports Mixed Q1 2026 Results with Strong International Growth Offset by Domestic Weakness
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported Q1 2026 financial results showing RMB...
WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
WuXi AppTec Co., Ltd. (SHA: 603259; HKG: 2359), China’s leading integrated Contract Research Organization (CRO),...
Thermo Fisher Scientific Reports 6% Revenue Growth in Q1 2026 Driven by Innovative Product Launches and Strategic AI Collaboration
Thermo Fisher Scientific Inc. (NYSE: TMO) announced first-quarter 2026 financial results with revenue growing 6%...
Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds
Roche AG (SWX: ROP, OTCMKTS: RHHBY) reported first-quarter 2026 group sales of CHF 14.7 billion...
Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has released its first quarter 2026...
Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance
Boston Scientific Corporation (NYSE: BSX) has released its first quarter 2026 financial results, reporting group...
Danaher Q1 Earnings Beat Expectations as Bioprocessing Strength Offsets Cepheid Weakness
Danaher Corporation (NYSE: DHR) reported first-quarter 2026 revenues of $6.0 billion, up 3.5% year-over-year, with...
Abbott Reports 3.8% YOY Revenue Growth in Q1 2026, Led by Diagnostics and Medical Devices
Abbott Laboratories (NYSE: ABT) announced its financial results for the first quarter of 2026, reporting...
Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance
Johnson & Johnson (J&J, NYSE: JNJ) reported first-quarter 2026 results on April 14, 2026, showcasing...
MicroPort Scientific Returns to Profitability as Global Access Platform Drives 78.8% Revenue Surge
MicroPort Scientific Corp. (HKG: 0853) announced its 2025 full-year financial results, reporting a return to...
Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology/CNS Segment Strength
Luye Pharma Group (HKG: 2186) has announced its 2025 financial results, reporting RMB 6.308 billion...
Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955), a controlling subsidiary of Luye Pharma Group (HKG:...
Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) reported exceptional commercial performance in its 2025 financial results,...
RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai’ai and Disitamab Vedotin
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) reported RMB 3.251 billion (USD 470 million) in...
Hansoh Pharma Reports 22.6% Revenue Growth in 2025, Driven by Oncology and $4.54B in Global Licensing Deals
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced robust 2025 financial results, with RMB 15.028...
Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M
Insilico Medicine (HKG: 3696), a pioneer in generative AI-driven drug discovery, released its 2025 financial...
CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline
CStone Pharmaceuticals (HKG: 2616) reported 2025 financial results, with annual sales declining 33.8% YoY to...
Grand Pharma 2025 Revenue HKD 12.28B – Innovative Products Hit 50% of Sales, Radiopharma Soars 61%
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) reported 2025 financial results, with revenue rising 5.5%...
Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%
Simcere Pharmaceutical Group (HKG: 2096) reported 2025 financial results, with revenue rising 16.5% YoY to...